Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Dmitry Bichev et al.|European Journal of Cancer|2011Cited by 615